Advertisement

Topics

Fennec Provides Corporate Update and Announces Second Quarter 2017 Results / SIOPEL 6 Results expected Q4 2017 - $7.6 million financing led by VENBIO Select Advisor in June 2017

06:04 EDT 11 Aug 2017 | FinanzNachrichten

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (Marketwired) -- 08/11/17 -- Fennec Pharmaceuticals Inc. (TSX: FRX) (OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodiu...

Original Article: Fennec Provides Corporate Update and Announces Second Quarter 2017 Results / SIOPEL 6 Results expected Q4 2017 - $7.6 million financing led by VENBIO Select Advisor in June 2017

NEXT ARTICLE

More From BioPortfolio on "Fennec Provides Corporate Update and Announces Second Quarter 2017 Results / SIOPEL 6 Results expected Q4 2017 - $7.6 million financing led by VENBIO Select Advisor in June 2017"

Quick Search
Advertisement